These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 20459394

  • 21. The foundation role of beta blockers across the cardiovascular disease spectrum: a year 2009 update.
    Black HR, Greenberg BH, Weber MA.
    Am J Med; 2010 Nov; 123(11):S2. PubMed ID: 21035578
    [Abstract] [Full Text] [Related]

  • 22. [Heart rate variability dynamics during treatment of arterial hypertension].
    Riabykina GV, Chazova IE, Mychka VB, Shutova LI, Shishova TV, Liutikova LN, Kozhemiakina ESh, Shchedrina EV, Sobolev AV.
    Kardiologiia; 2008 Nov; 48(7):18-24. PubMed ID: 18789021
    [Abstract] [Full Text] [Related]

  • 23. Nitric oxide mechanisms of nebivolol.
    Maffei A, Lembo G.
    Ther Adv Cardiovasc Dis; 2009 Aug; 3(4):317-27. PubMed ID: 19443516
    [Abstract] [Full Text] [Related]

  • 24. The impact of third-generation beta-blocker antihypertensive treatment on endothelial function and the prothrombotic state: effects of smoking.
    Vyssoulis GP, Marinakis AG, Aznaouridis KA, Karpanou EA, Arapogianni AN, Cokkinos DV, Stefanadis CI.
    Am J Hypertens; 2004 Jul; 17(7):582-9. PubMed ID: 15233977
    [Abstract] [Full Text] [Related]

  • 25. Therapeutic dose of nebivolol, a nitric oxide-releasing beta-blocker, reduces atherosclerosis in cholesterol-fed rabbits.
    de Nigris F, Mancini FP, Balestrieri ML, Byrns R, Fiorito C, Williams-Ignarro S, Palagiano A, Crimi E, Ignarro LJ, Napoli C.
    Nitric Oxide; 2008 Aug; 19(1):57-63. PubMed ID: 18435936
    [Abstract] [Full Text] [Related]

  • 26. The effect of low-dose carvedilol, nebivolol, and metoprolol on central arterial pressure and its determinants: a randomized clinical trial.
    Studinger P, Tabák ÁG, Chen CH, Salvi P, Othmane TE, Torzsa P, Kapocsi J, Fekete BC, Tislér A.
    J Clin Hypertens (Greenwich); 2013 Dec; 15(12):910-7. PubMed ID: 24119182
    [Abstract] [Full Text] [Related]

  • 27. [Role of the L-arginine/nitric oxide system in the action of nebivolol].
    Brodde OE, Philipp T.
    Dtsch Med Wochenschr; 2006 Nov 10; 131(45):2545-50. PubMed ID: 17091442
    [Abstract] [Full Text] [Related]

  • 28. Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis.
    Van Bortel LM, Fici F, Mascagni F.
    Am J Cardiovasc Drugs; 2008 Nov 10; 8(1):35-44. PubMed ID: 18303936
    [Abstract] [Full Text] [Related]

  • 29. A review of the safety and efficacy of nebivolol in the mildly hypertensive patient.
    Cockcroft J.
    Vasc Health Risk Manag; 2007 Nov 10; 3(6):909-17. PubMed ID: 18200810
    [Abstract] [Full Text] [Related]

  • 30. Carvedilol in hypertension treatment.
    Stafylas PC, Sarafidis PA.
    Vasc Health Risk Manag; 2008 Nov 10; 4(1):23-30. PubMed ID: 18629377
    [Abstract] [Full Text] [Related]

  • 31. The effects of newer beta-adrenoceptor antagonists on vascular function in cardiovascular disease.
    Wehland M, Grosse J, Simonsen U, Infanger M, Bauer J, Grimm D.
    Curr Vasc Pharmacol; 2012 May 10; 10(3):378-90. PubMed ID: 22022769
    [Abstract] [Full Text] [Related]

  • 32. The role of nitric oxide in improving endothelial function and cardiovascular health: focus on nebivolol.
    Bakris GL, Basile JN, Giles TD, Taylor AA.
    Am J Med; 2010 Jul 10; 123(7 Suppl 1):S2-8. PubMed ID: 20609695
    [Abstract] [Full Text] [Related]

  • 33. Targeting nitric oxide with drug therapy.
    Mason RP, Cockcroft JR.
    J Clin Hypertens (Greenwich); 2006 Dec 10; 8(12 Suppl 4):40-52. PubMed ID: 17170605
    [Abstract] [Full Text] [Related]

  • 34. One size does not fit all: the role of vasodilating beta-blockers in controlling hypertension as a means of reducing cardiovascular and stroke risk.
    Basile JN.
    Am J Med; 2010 Jul 10; 123(7 Suppl 1):S9-15. PubMed ID: 20609697
    [Abstract] [Full Text] [Related]

  • 35. Beta-adrenoceptor antagonists in elderly patients with chronic heart failure: therapeutic potential of third-generation agents.
    Coats AJ.
    Drugs Aging; 2006 Jul 10; 23(2):93-9. PubMed ID: 16536633
    [Abstract] [Full Text] [Related]

  • 36. Meta-analysis of carvedilol versus beta 1 selective beta-blockers (atenolol, bisoprolol, metoprolol, and nebivolol).
    DiNicolantonio JJ, Lavie CJ, Fares H, Menezes AR, O'Keefe JH.
    Am J Cardiol; 2013 Mar 01; 111(5):765-9. PubMed ID: 23290925
    [Abstract] [Full Text] [Related]

  • 37. Acute and 14-day hepatic venous pressure gradient response to carvedilol and nebivolol in patients with liver cirrhosis.
    Silkauskaitė V, Kupčinskas J, Pranculis A, Jonaitis L, Petrenkienė V, Kupčinskas L.
    Medicina (Kaunas); 2013 Mar 01; 49(11):467-73. PubMed ID: 24823927
    [Abstract] [Full Text] [Related]

  • 38. Nebivolol: a third-generation beta-blocker for hypertension.
    Cheng JW.
    Clin Ther; 2009 Mar 01; 31(3):447-62. PubMed ID: 19393838
    [Abstract] [Full Text] [Related]

  • 39. What is the role, if any, for beta-blockers as initial therapy for uncomplicated hypertension?
    Pedersen ME, Cockcroft JR.
    Curr Opin Cardiol; 2009 Jul 01; 24(4):325-32. PubMed ID: 19417638
    [Abstract] [Full Text] [Related]

  • 40. Beta-blockers in the management of hypertension: focus on nebivolol.
    Wojciechowski D, Papademetriou V.
    Expert Rev Cardiovasc Ther; 2008 Apr 01; 6(4):471-9. PubMed ID: 18402537
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.